As of 2025-10-31, the Intrinsic Value of Tandem Diabetes Care Inc (TNDM) is 1.43 USD. This TNDM valuation is based on the model Discounted Cash Flows (EBITDA Exit 10Y). With the current market price of 14.59 USD, the upside of Tandem Diabetes Care Inc is -90.20%.
The range of the Intrinsic Value is (0.45) - 3.96 USD
Based on its market price of 14.59 USD and our intrinsic valuation, Tandem Diabetes Care Inc (TNDM) is overvalued by 90.20%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (101.93) - (25.38) | (37.99) | -360.4% |
| DCF (Growth 10y) | (17.73) - (52.15) | (23.51) | -261.1% |
| DCF (EBITDA 5y) | (5.07) - (4.13) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (0.45) - 3.96 | 1.43 | -90.2% |
| Fair Value | -15.20 - -15.20 | -15.20 | -204.20% |
| P/E | (59.35) - (72.97) | (70.85) | -585.6% |
| EV/EBITDA | (17.87) - (15.29) | (18.79) | -228.8% |
| EPV | (27.06) - (37.86) | (32.46) | -322.5% |
| DDM - Stable | (31.21) - (138.77) | (84.99) | -682.5% |
| DDM - Multi | (1.82) - (6.30) | (2.82) | -119.3% |
| Market Cap (mil) | 985.85 |
| Beta | 0.99 |
| Outstanding shares (mil) | 67.57 |
| Enterprise Value (mil) | 1,230.88 |
| Market risk premium | 4.60% |
| Cost of Equity | 8.40% |
| Cost of Debt | 5.50% |
| WACC | 7.62% |